BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38330136)

  • 21. Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy.
    Zeng J; Ding X; Ding J; Wang X
    Front Immunol; 2023; 14():1275957. PubMed ID: 38022621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Origins, genetic landscape, and emerging therapies of small cell lung cancer.
    Semenova EA; Nagel R; Berns A
    Genes Dev; 2015 Jul; 29(14):1447-62. PubMed ID: 26220992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
    Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
    J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
    Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
    Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
    Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
    Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Club cells employ regeneration mechanisms during lung tumorigenesis.
    Chen Y; Toth R; Chocarro S; Weichenhan D; Hey J; Lutsik P; Sawall S; Stathopoulos GT; Plass C; Sotillo R
    Nat Commun; 2022 Aug; 13(1):4557. PubMed ID: 35931677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium.
    Chen J; Guanizo A; Luong Q; Jayasekara WSN; Jayasinghe D; Inampudi C; Szczepny A; Garama DJ; Russell PA; Ganju V; Cain JE; Watkins DN; Gough DJ
    Oncogene; 2022 Jan; 41(1):138-145. PubMed ID: 34675406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.
    Llabata P; Torres-Diz M; Gomez A; Tomas-Daza L; Romero OA; Grego-Bessa J; Llinas-Arias P; Valencia A; Esteller M; Javierre BM; Zhang X; Sanchez-Cespedes M
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34493659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.
    Udyavar AR; Hoeksema MD; Clark JE; Zou Y; Tang Z; Li Z; Li M; Chen H; Statnikov A; Shyr Y; Liebler DC; Field J; Eisenberg R; Estrada L; Massion PP; Quaranta V
    BMC Syst Biol; 2013; 7 Suppl 5(Suppl 5):S1. PubMed ID: 24564859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.
    Grzeskowiak CL; Kundu ST; Mo X; Ivanov AA; Zagorodna O; Lu H; Chapple RH; Tsang YH; Moreno D; Mosqueda M; Eterovic K; Fradette JJ; Ahmad S; Chen F; Chong Z; Chen K; Creighton CJ; Fu H; Mills GB; Gibbons DL; Scott KL
    Nat Commun; 2018 Jul; 9(1):2732. PubMed ID: 30013058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bromodomain and hedgehog pathway targets in small cell lung cancer.
    Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
    Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance.
    Mao G; Mu Z; Wu DA
    Acta Biochim Biophys Sin (Shanghai); 2021 Nov; 53(11):1484-1494. PubMed ID: 34605863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
    Ninomaru T; Hata A; Hara S; Komatsu M
    Thorac Cancer; 2022 Aug; 13(16):2394-2397. PubMed ID: 35793695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer.
    Huang F; Huffman KE; Wang Z; Wang X; Li K; Cai F; Yang C; Cai L; Shih TS; Zacharias LG; Chung A; Yang Q; Chalishazar MD; Ireland AS; Stewart CA; Cargill K; Girard L; Liu Y; Ni M; Xu J; Wu X; Zhu H; Drapkin B; Byers LA; Oliver TG; Gazdar AF; Minna JD; DeBerardinis RJ
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33079728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different pattern of expression of cellular oncogenes in human non-small-cell lung cancer cell lines.
    Kiefer PE; Wegmann B; Bacher M; Erbil C; Heidtmann H; Havemann K
    J Cancer Res Clin Oncol; 1990; 116(1):29-37. PubMed ID: 1690210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TRIP13 promotes lung cancer cell growth and metastasis through AKT/mTORC1/c-Myc signaling.
    Cai W; Ni W; Jin Y; Li Y
    Cancer Biomark; 2021; 30(2):237-248. PubMed ID: 33136091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transformation from EGFR/PTEN co-mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis.
    Hayashi T; Takamochi K; Kohsaka S; Kishikawa S; Suehara Y; Takahashi F; Suzuki K; Saito T; Yao T
    Pathol Int; 2020 May; 70(5):295-299. PubMed ID: 32162763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.